Bath & Body Works (NYSE:BBWI) has suddenly become one of retail’s more interesting activist situations. Barington Capital has reportedly built a roughly 0.38% stake and wants the company to explore a sale. The Bath & Body Works Sale debate is now becoming a key issue for investors. The activist also wants board representation and is preparing a letter to directors. Yet there is no announced sale process, no disclosed adviser, and no identified buyer. That gap is what makes this story worth watching. Barington argues that the brand is undervalued and could attract private equity interest. Management, however, says its turnaround is starting to show measurable progress. Second-quarter sales still declined, and store traffic remains weak. At the same time, digital growth returned, new distribution channels expanded, and free cash flow guidance increased. So investors now face a simple question: does Bath & Body Works sell while expectations remain low, or does the board give management more time to prove its 2027 recovery plan?
Weak Store Traffic Gives Barington A Clear Opening
Barington’s argument starts with a business that still has visible operating pressure. Bath & Body Works reported a 2.3% decline in second-quarter net sales to $1.5 billion. That was better than management expected, but it was still a decline. U.S. and Canadian store sales fell 5.4%, while body care remained down by a mid-single-digit percentage. Management also expects third-quarter sales to decline between 2.5% and 5%.
The biggest issue is traffic. CEO Daniel Heaf repeatedly acknowledged that store visits remain under pressure. Management has already completed a major merchandising reset across its store base. Conversion has improved, but attracting shoppers remains harder.
That gives an activist a straightforward message. The company owns a powerful brand, yet its core store channel is still shrinking. Barington can argue that shareholders should not wait indefinitely for a recovery. The Bath & Body Works Sale argument becomes more relevant if store traffic fails to stabilize.
There is also urgency from the stock price. Shares entered the activist campaign down roughly 13% for 2026. Barington reportedly believes management instability and weak execution have contributed to that underperformance.
Cash Generation Keeps Strategic Optionality Alive Store Traffic Still Determines The Outcome
Bath & Body Works now sits between activist pressure and an unfinished turnaround. Barington wants the board to explore a sale, while management points to digital growth, distribution expansion, cost savings and higher free cash flow guidance. Investors need to judge whether those improvements can offset weak store traffic before a credible transaction process emerges.
Strong free cash flow, profitable stores and expanding digital, Amazon, Ulta and international channels could support either a stronger standalone recovery or buyer interest.
Persistent store traffic weakness and declining sales could undermine the turnaround, while tariffs, input costs and added marketing spending pressure near-term economics.
Watch whether store traffic stabilizes and whether Barington’s campaign produces a formal strategic review, disclosed adviser, credible buyer or acquisition proposal.
Bath & Body Works combines compressed valuation and substantial cash generation with unresolved store-traffic weakness. The key question is whether management can demonstrate enough 2027 recovery momentum before activist pressure turns into a credible transaction process.
Still, weak traffic alone does not guarantee a sale. The board must decide whether these problems are structural or fixable.
Strong Cash Flow Could Make Private Equity Take A Look At A Bath & Body Works Sale
Private equity does not need a business to be growing rapidly. It usually needs predictable cash generation and room for operational improvement. Bath & Body Works offers both characteristics, even while sales remain under pressure.
Management now expects about $650 million of free cash flow for fiscal 2026, up from its previous $600 million forecast. Capital expenditures should total roughly $240 million. The company also redeemed $250 million of its 2029 notes in August. These figures matter because cash flow helps support debt repayment in a leveraged acquisition.
The store portfolio also looks healthier than the headline traffic weakness suggests. Management says virtually every store generates four-wall profit. Around 60% of the North American fleet is now located off-mall. Bath & Body Works continues closing stores in weaker malls while adding locations in more convenient formats.
There are additional cost levers. The company expects roughly $200 million of Fuel for Growth savings this year, exceeding its original target. It is also exiting Home Care, which creates complexity while producing less than 1% of annual sales.
For a financial buyer, that creates an interesting setup. The challenge is not rescuing a cash-burning retailer. It is deciding what the existing cash flows are worth.
Early Turnaround Progress Could Make The Board Resist
Barington may want a sale, but management has a credible reason to ask for more time. The turnaround is still young, and several operating indicators improved during the second quarter.
Digital sales returned to growth after years of weakness. Direct-channel revenue increased 3%, helped by stronger conversion and a lower free-shipping threshold. Amazon sales more than tripled from the first quarter. Bath & Body Works also launched inside roughly 600 Ulta Beauty stores. Management says it has not observed cannibalization of its stores or website so far.
Product innovation is also generating some encouraging data. Fruit Fusion exceeded internal sales expectations, while several product forms sold out. Management plans to extend the franchise instead of treating it as a seasonal release. International retail sales rose 9% despite geopolitical disruption in the Middle East.
None of those figures proves that a turnaround has arrived. Heaf explicitly said the improvements are not broad enough to represent a full business inflection. Store traffic remains the main weakness. That creates another complication for the Bath & Body Works Sale thesis.
Still, management’s strategic target is revenue growth in 2027. That creates a difficult timing question. Would selling now monetize an undervalued asset, or transfer the upside from a possible recovery to a private buyer?
The Missing Buyer & Missing Price Remain The Biggest Questions
This is where the activist story becomes more complicated. Barington can push for a transaction, but there is still no disclosed buyer and no formal auction. Bath & Body Works has not announced a strategic review. No acquisition price has been reported either.
That means investors should separate the activist’s objective from an actual deal process. A Bath & Body Works Sale remains a possibility rather than a confirmed transaction.
A potential private equity buyer would have several things to consider. Bath & Body Works generates meaningful cash and operates a recognizable national brand. Its store base remains profitable, while Amazon, Ulta, digital, and international channels provide additional distribution opportunities. Cost savings could also support returns.
But there are meaningful risks. Store traffic remains weak. Overall revenue is still declining. Management is spending another $35 million on its Consumer First Formula, primarily through marketing. Tariffs and input costs are creating roughly $30 million of additional pressure in the second half.
A buyer would therefore need to price both the brand’s durability and its turnaround risk. Financing conditions matter as well.
That is why an actual bid would tell investors much more than activist rhetoric alone. Until a credible buyer appears, the sale thesis remains a possibility rather than a transaction.
Final Thoughts
Barington’s involvement changes the discussion around Bath & Body Works, but it does not determine the outcome. The activist now has to convince other shareholders that a sale creates more value than management’s standalone plan. Management has to show that early gains in digital, innovation, and distribution can eventually offset weak store traffic.
The valuation helps explain why the Bath & Body Works Sale debate is happening. As of September 10, Bath & Body Works traded at roughly 1.04x LTM enterprise value to revenue, 5.68x LTM EV/EBITDA, and 6.98x LTM EV/EBIT. Its LTM price-to-sales multiple stood near 0.49x, while its trailing P/E was about 4.54x.
Those are compressed multiples for a business still producing substantial free cash flow. They also reflect real concerns about declining sales, traffic pressure, and turnaround execution.
That leaves the board with an important valuation question. A takeover premium alone may not be enough if management believes earnings and revenue can recover in 2027. Conversely, a sufficiently high acquisition multiple could shift the calculation.
The valuation is compressed; the transaction still needs a buyer.
For now, Bath & Body Works has an activist seeking a sale, but no buyer has surfaced. The next major signal will be whether Barington’s campaign turns into an actual process—and what valuation any bidder is willing to put on the brand.
Disclaimer: We do not hold any positions in the above stock(s). Read our full disclaimer here.
